Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
9.51
+0.22 (2.37%)
At close: Apr 28, 2026, 4:00 PM EDT
9.50
-0.01 (-0.11%)
After-hours: Apr 28, 2026, 4:32 PM EDT
Upstream Bio Employees
Upstream Bio had 75 employees as of December 31, 2025. The number of employees increased by 23 or 44.23% compared to the previous year.
Employees
75
Change (1Y)
23
Growth (1Y)
44.23%
Revenue / Employee
$38,053
Profits / Employee
-$1,912,573
Market Cap
517.53M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 75 | 23 | 44.23% |
| Dec 31, 2024 | 52 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| Lyell Immunopharma | 300 |
| 4D Molecular Therapeutics | 196 |
| ADC Therapeutics | 193 |
| Verastem | 102 |
| enGene Therapeutics | 82 |
| Tectonic Therapeutic | 60 |
| Fulcrum Therapeutics | 55 |
UPB News
- 11 days ago - Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference - GlobeNewsWire
- 4 weeks ago - Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data - Benzinga
- 4 weeks ago - Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Upstream Bio Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Upstream Bio Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - GlobeNewsWire
- 2 months ago - Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewsWire